Reading the Mounjaro patient leaflet: what matters most

Why the leaflet exists and what it actually contains

Every licensed medicine sold in the UK must include a patient information leaflet, written to a standard set by the MHRA. The Mounjaro PIL is not marketing material; it is a regulatory document, drafted against the SmPC (Summary of Product Characteristics) and reviewed by the medicines regulator before the pen reaches a pharmacy shelf. If you want the most authoritative patient-level reference for tirzepatide, the NHS tirzepatide medicines page is a reliable companion alongside your PIL, written specifically to help patients navigate the same information.

The leaflet is structured in a familiar order: what Mounjaro is and what it is used for; what you need to know before using it; how to use it; possible side effects; how to store it; and the contents of the pack. That last section matters more than people expect, it describes the pen's components and what a normal pen looks like, which is useful context if you are checking whether a pen you have received looks right.

The mechanism section explains that tirzepatide works on two gut-hormone receptors (GIP and GLP-1), slowing gastric emptying and reducing appetite. This dual-agonist action is what makes Mounjaro distinct from the single-pathway GLP-1 medicines; our tirzepatide overview unpacks the clinical meaning of that difference in more detail. If you would like to read through the full regulatory text yourself, our Mounjaro leaflet page reproduces the PIL so you can work through it alongside this guidance.

The side-effect section: reading it without alarm

This is the part that most people turn to first, and it is easy to find alarming if you read it as a list of things that will happen rather than things that have been reported across large clinical trials. The frequency categories help: "very common" means more than 1 in 10 people reported it; "rare" means fewer than 1 in 1,000.

The most frequently reported effects in the Mounjaro trials were gastrointestinal, nausea, diarrhoea, constipation, vomiting, indigestion, and reflux. Most people find these are sharpest in the days after starting or after a dose increase, and they settle as the body adjusts. That pattern is worth knowing because the leaflet lists the effects without necessarily conveying the typical time course, which is where a clinical conversation adds real value.

The leaflet also flags effects that are uncommon but serious, including acute pancreatitis. On that point, the MHRA issued a Drug Safety Update in January 2026 specifically about GLP-1 medicines, reinforcing that severe and persistent stomach pain radiating to the back, with or without vomiting, should prompt urgent medical attention. If you want to look into that further, the MHRA Yellow Card scheme is where patients can report suspected side effects and read published safety communications. You should also know that Mounjaro carries a Black Triangle (▼) designation, meaning the MHRA actively collects additional safety data, your reports genuinely contribute to that.

One thing the leaflet does not do is tell you what to do if a side effect persists. For that, you need your prescriber. If you have questions after reading yours, our support team is available seven days a week.

What the leaflet cannot decide for you

Reading the leaflet carefully is sensible. Using it to make your own dosing decisions is a different matter, and the leaflet itself is explicit that tirzepatide is started at 2.5 mg and increased by the prescriber, typically at four-week intervals. The schedule exists because the body needs time to adjust before each step up, going faster increases the chance of GI side effects, and going slower is sometimes the right clinical call. The leaflet describes the licensed schedule; it cannot weigh that against your individual response.

Similarly, the contraindications section lists circumstances where Mounjaro is not suitable (certain thyroid conditions, a history of pancreatitis, pregnancy, breastfeeding, and others) but it is your prescriber's job to establish whether any of those apply to you before treatment starts. Tirzepatide is not recommended during pregnancy or for anyone under 18, and women using oral contraceptives should discuss the interaction with their prescriber, since the PIL notes that absorption of the pill may be temporarily reduced in the early weeks of treatment.

If you are weighing up treatment options more broadly, the weight loss treatment overview covers how different licensed medicines compare. And if you are curious about what treatment with nume actually costs, our page on the 2025 Lilly price increase sets out the honest market context. Prescription-only treatment through a GPhC-registered pharmacy is the only safe legal route; the leaflet inside the box is one part of what makes that route verifiable.

When to reach out rather than re-read the leaflet

There is a version of reading a patient leaflet that is thorough and productive, and there is a version that becomes anxious scrolling through every listed rare effect at 11pm. If you have already read your leaflet twice and still feel uncertain, that is a sign to ask a question, not to keep reading.

A question our prescribers hear regularly: "Is this side effect normal at my dose?" The leaflet can tell you whether that effect appears on the list, but a clinician can tell you whether what you are experiencing fits the expected pattern, and what, if anything, to do about it. Every patient treated through our Mounjaro service has access to priority aftercare seven days a week for exactly this reason.

The PIL is also not updated in real time, it reflects the information available at the time of the last SmPC revision. For the most current guidance, particularly on interactions and emerging safety signals, the detailed patient information page on our site draws on the latest published sources. For a downloadable reference, the leaflet PDF resource pulls together the key sections in an accessible format. If you are working through a specific clinical question and want to speak with someone directly, starting a free consultation with our prescribers is the straightforward next step.